Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-08-14
Schrodinger, Inc.
Schrödinger sells molecular modeling and discovery workflow software to pharma, biotech, and materials customers while also monetizing partnered and proprietary drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow control drives the real upside
The credible upside case is not a single drug win. It is proving that AI increases billable discovery throughput on a sticky hosted workflow, while partnerships keep therapeutics as upside rather than a cash sink.

Analysis

Thesis
Schrödinger’s best five-year path is a business-model upgrade: if hosted delivery, AI-assisted workflows, and program-linked pricing turn its simulation stack into a deeper operating layer for pharma discovery, rising molecular design throughput can convert into better recurring revenue and a meaningful rerating without needing a single blockbuster drug win.
Last Economy Alignment
AI should expand the amount of molecular work run on its stack, and hosted usage pricing gives it a way to monetize that growth. But it does not control the core compute layer, and generic agents or internal pharma stacks could weaken interface ownership if workflow control slips.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.2x (from 5 most recent analyses)
Reasoning
The upside case is a cleaner, stickier software story rather than a binary biotech outcome. If hosted contracts deepen usage, AI expands billable discovery throughput, and selective partnerships keep therapeutics from reabsorbing capital, the market can start valuing the business as a higher-quality discovery operating layer instead of a lumpy tools vendor.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is value capture, not scientific relevance. Schrödinger likely stays useful, but the equity case weakens if hosted delivery only changes accounting, if AI raises usage without raising paid workflow control, or if pharma internal stacks sit above its products. Q4 renewals, early Bunsen utilization, and partner-led clinical monetization are the clearest gates.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.44
They help drug researchers run far more molecular work as AI speeds discovery, and they can capture some of that through hosted workflow and usage pricing. The risk is that pharma teams or generic AI agents treat them as a back-end engine instead of the place where the real work gets organized.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.57
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case